论文部分内容阅读
目的:应用抗血管生成药物酞咪哌啶酮进行乳腺癌肝转移患者的维持治疗,探讨其疗效以及安全性。方法:完成一线有效化疗的乳腺癌肝转移患者32例,随机分为维持治疗组和对照组。维持治疗组给予酞咪哌啶酮口服100mg/d,对照组定期随访观察。比较两组患者无进展生存期(PFS)、转移后中位生存期(MSR),观察近期临床疗效、患者生活质量以及不良反应发生情况。结果:与对照组比较,维持治疗组PFS延长(P<0.05)、MSR延长(P>0.05),总有效率高于对照组(P<0.05)。Karnofsky评分改善率高于对照组(P<0.05),未出现严重不良反应。结论:一线有效治疗后给予酞咪哌啶酮维持治疗,可以提高临床治疗效果、延长乳腺癌肝转移患者的无进展生存期,毒性低、安全性好,能够改善患者的生活质量,为乳腺癌肝转移维持治疗提供新的治疗思路。
OBJECTIVE: To evaluate the efficacy and safety of thalidomide, an antiangiogenic drug, in the maintenance of patients with liver metastases from breast cancer. Methods: Thirty-two patients with liver metastasis from first-line effective chemotherapy were randomly divided into maintenance treatment group and control group. The maintenance treatment group was treated with thalidomide orally 100mg / d, the control group were followed up regularly. The progression-free survival (PFS), median survival (MSR) after metastasis were compared between two groups. The clinical efficacy, quality of life and adverse reactions were observed. Results: Compared with the control group, the maintenance treatment group prolonged PFS (P <0.05), MSR prolonged (P> 0.05), and the total effective rate was higher than that of the control group (P <0.05). Karnofsky score higher than the control group (P <0.05), no serious adverse reactions. Conclusion: The first-line effective treatment of thalidomide maintenance treatment can improve the clinical treatment effect, prolong the progression-free survival of patients with liver metastases of breast cancer, low toxicity, good safety, can improve the quality of life of patients with breast cancer Liver metastasis maintenance treatment to provide new treatment ideas.